Preclinical systems such as patient-derived xenografts are providing unprecedented insight into tumor biology and helping bridge the gap between discovery and clinical translation.
As nearly 90 percent of drugs fail in human trials, researchers are turning to patient-derived cells, engineered tissues, and AI to better predict human responses and reduce costly late-stage failures.
Investments in solid tumor targets and autoimmune disease, success for a peanut allergy patch, a promising CAR T cell therapy for stiff person syndrome, and more led the news this week.